nobel prize glp 1 Joel Habener Receives Breakthrough in Life Sciences for Contributions to GLP-1 Medications Lotte Bjerre Knudsen, 2025 Breakthrough
Description
Glucagon-like peptide 1 receptor agonists (GLP1-RA) are indicated for the treatment of type 2 diabetes and more recently for weight loss
hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12)
Because of these factors, individuals may notice improvements not only in their digestion but also in their energy levels
The Reality of Muscle Loss on Anti-Obesity Medications: What the Data Actually Shows When you lose 30, 50, or 100 pounds, you are not just losing fatyou are also shedding lean mass
By Amina Niasse NEW YORK, June 2 (Reuters) - Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee health plan
The conversation around GLP-1s is slowly shifting from short term weight loss to long term strategies for maintenance and offboarding.
